Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 41Radiotherapy 38Cisplatin 35Oxaliplatin 32Leucovorin 24Paclitaxel 22Irinotecan 20Docetaxel 17Neoadjuvant Therapy 14Carboplatin 13Radiation 12Capecitabine 12Surgical Procedures, Operative 10Cetuximab 8Biopsy 8durvalumab 7Gefitinib 7Chemotherapy, Adjuvant 7tremelimumab 6pembrolizumab 6Nivolumab 6Magnetic Resonance Spectroscopy 6Folfox protocol 6Taxes 5Immunohistochemistry 5Endoscopy 5Gene Expression Profiling 4Epirubicin 4Drug Therapy 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma Of Esophagus × futibatinib × Clear all
NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡